An observational study in Psoriatic Arthritis, Upadacitinib and Interleukin-17 Inhibitors, sponsored by Peking University First Hospital. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Peking University First Hospital · Observational
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life. Although targeted therapies such as Janus kinase inhibitors and interleukin-17 inhibitors have demonstrated efficacy in randomized controlled trials, real-world comparative evidence between these treatment strategies remains limited.
This observational cohort study aims to compare the real-world effectiveness and safety of upadacitinib and interleukin-17 inhibitors in patients with PsA over a 24-week follow-up period. By evaluating clinical outcomes under routine clinical practice conditions, this study seeks to provide evidence to support individualized treatment selection in PsA management.
This is a real-world, observational cohort study conducted at Peking University First Hospital. Adult patients diagnosed with psoriatic arthritis will be enrolled and followed for 24 weeks in routine clinical practice.
Participants will be categorized into two cohorts based on treatment exposure at baseline: patients receiving upadacitinib and patients receiving interleukin-17 inhibitors. Treatment decisions are made by treating physicians according to standard clinical practice and are not influenced by the study protocol.
Clinical assessments will be performed at baseline and during routine follow-up visits within the 24-week observation period. Effectiveness outcomes will be evaluated across musculoskeletal and dermatologic domains, and safety outcomes will be monitored throughout follow-up. This study does not involve experimental interventions.
579 studies on the registry are indexed under Arthritis, Psoriatic; 132 are open to participants now.
This study's enrollment of 70 is below the median of 300 across 235 observational studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Peking University First Hospital is the lead sponsor of 378 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Diagnosis of psoriatic arthritis according to established classification criteria
Exclusion Criteria:
Adult patients with psoriatic arthritis receiving upadacitinib as part of routine clinical care and followed for 24 weeks.
Adult patients with psoriatic arthritis receiving interleukin-17 inhibitors (e.g., secukinumab or ixekizumab) as part of routine clinical care and followed for 24 weeks.
Clinical effectiveness of treatment
Changes in joint and skin disease activity assessed using validated clinical measures during the 24-week follow-up period.
Time frame: Baseline to Week 24
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University First Hospital